NEW YORK (GenomeWeb) – Caprion Biosciences said today that it has acquired immune monitoring firm Serametrix.
It said that the purchase will provide it access to Carlsbad, California-based Serametrix's expertise in analysis of myeloid-derived suppressor cells (MDSC) and its operations in the US, UK, Australia, and China.
"Joining forces with Serametrix enables Caprion to strengthen its immunology biomarker offering and provides CAP and CLIA-certified services for supporting Phase 1 through Phase 4 trials from seven different strategic locations in North America, Europe, and Asia," Caprion President and CEO Martin LeBlanc said in a statement.
"We fully share the vision of Caprion to provide cutting edge immune-monitoring solutions enabling the development of innovative immune and cell therapies," said Phoebe Bonner, CEO of Serametrix.
Financial and other details of the acquisition were not disclosed.